Neogenomics (NEO) closed at $16.02 on November 13, 2026, down 3.1% from the previous close, on volume of 1,805,509 shares (30-day average 1,889,528).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Diagonal Call Spread | 18-Dec-26 : 21-May-2725 : 26 C | 1,800 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
NeoGenomics Earnings Call Highlights Growth and Guidance
TipRanks (Wed, 11-Nov 7:29 PM ET)
NeoGenomics to Participate in Upcoming Investor Conferences
Business Wire (Fri, 6-Nov 7:05 AM ET)
NeoGenomics Reports Third Quarter 2026 Results
Business Wire (Wed, 28-Oct 4:05 PM ET)
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
Business Wire (Thu, 15-Oct 7:05 AM ET)
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
Business Wire (Wed, 14-Oct 7:05 AM ET)
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
Business Wire (Mon, 5-Oct 4:05 PM ET)
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire (Tue, 1-Sep 7:05 AM ET)
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
Business Wire (Wed, 26-Aug 4:17 PM ET)
NeoGenomics Lifts Outlook as NGS Revenue Jumps 26% and Margins Improve
Market Chameleon (Wed, 29-Jul 7:51 AM ET)
Medicare Coverage for NeoGenomics' PanTracer LBx Expands Access to Advanced Liquid Biopsy Testing
Market Chameleon (Mon, 16-Mar 4:14 AM ET)
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Neogenomics trades on the NASDAQ stock market under the symbol NEO.
As of November 13, 2026, NEO stock price declined to $16.02 with 1,805,509 million shares trading.
NEO has a beta of 0.48, meaning it tends to be less sensitive to market movements. NEO has a correlation of 0.01 to the broad based SPY ETF.
NEO has a market cap of $2.07 billion. This is considered a Mid Cap stock.
Last quarter Neogenomics reported $209 million in Revenue and $.07 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.03.
In the last 3 years, NEO traded as high as $21.22 and as low as $4.72.
The top ETF exchange traded funds that NEO belongs to (by Net Assets): IJR, FBT, VTI, IWM, VB.
NEO has outperformed the market in the last year with a return of +60.0%, while the SPY ETF gained +13.4%. In the last 3 month period, NEO beat the market returning -2.3%, while SPY returned -2.8%. However, in the most recent 2 weeks NEO has underperformed the stock market by returning -7.8%, while SPY returned -0.2%.
NEO support price is $16.02 and resistance is $17.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEO shares will trade within this expected range on the day.